Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences ( (PLSE) ) just unveiled an update.
On April 25, 2026, Pulse Biosciences reported updated late‑breaking data from its first‑in‑human feasibility study of the nPulse Cardiac Catheter System for atrial fibrillation, presented at the Heart Rhythm 2026 meeting in Chicago. The expanded cohorts showed 100% procedural success at six months in 95 evaluable patients, 96% procedural success at one year in 53 evaluable patients, and a 90% Kaplan‑Meier estimate of freedom from atrial arrhythmias at one year.
Investigators highlighted durable pulmonary vein isolation, short left atrial dwell and total procedure times, and low fluoroscopy exposure, suggesting a procedurally efficient profile for the non‑thermal nsPFA approach. With only 1.7% of 177 treated subjects experiencing a serious adverse event related to the primary safety endpoint, the results support the potential of the nPulse system to reshape expectations for catheter ablation outcomes and could strengthen Pulse Biosciences’ positioning in the emerging pulsed field ablation market.
The most recent analyst rating on (PLSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large and rising losses, and heavy cash burn) and a mixed technical backdrop. Offsetting factors are meaningful clinical/regulatory progress and several positive development milestones, while valuation support is limited due to negative earnings and no dividend yield.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company developing its proprietary nPulse technology, which delivers nanosecond pulsed field ablation energy to non‑thermally clear cells while sparing adjacent noncellular tissue. The company is focusing this platform on treating atrial fibrillation and exploring a select number of other markets where its approach could materially improve outcomes for patients and healthcare providers.
Average Trading Volume: 360,233
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.57B
Learn more about PLSE stock on TipRanks’ Stock Analysis page.